Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699121 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
A Phase 2 study of Primary Sclerosing Cholangitis (PSC), sponsored by LISCure Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 7
- Study locations
NCT06699121 is a Phase 2 study of Primary Sclerosing Cholangitis (PSC) that is actively recruiting participants, run by LISCure Biosciences. The registered enrollment target is 87 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT06699121, a Phase 2 study of Primary Sclerosing Cholangitis (PSC), is actively recruiting participants, sponsored by LISCure Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 7
- Study locations
Study Summary
The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LB-P8 low-dose
- DRUG LB-P8 high-dose
Study Locations (7)
California
- University of California Davis - Sacramento
Colorado
- UCHealth University of Colorado Hospital - Aurora
Iowa
- University Of Iowa Hospitals And Clinics - Iowa City
Maryland
- Mercy Medical Center - Baltimore
Minnesota
- Mayo Clinic - Rochester
Tennessee
- The Vanderbilt Clinic - Nashville
Washington
- Liver institute Northwest - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2025-11 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06699121
The ClinicalTrials.gov registry entry for NCT06699121 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LISCure Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Sclerosing Cholangitis (PSC) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06699121 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Colorado, Iowa.
Frequently Asked Questions
What is clinical trial NCT06699121 about?
NCT06699121 is a clinical study titled "A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC". The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.
What is the current status of trial NCT06699121?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2025-11. Estimated completion is 2029-02.
What conditions does trial NCT06699121 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis (PSC).
What interventions are being tested in trial NCT06699121?
The interventions under investigation include: Placebo (DRUG), LB-P8 low-dose (DRUG), LB-P8 high-dose (DRUG).
Who is sponsoring clinical trial NCT06699121?
This trial is sponsored by LISCure Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06699121 being conducted?
This trial has 7 study locations across California, Colorado, Iowa, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis (PSC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.